ICH Expansion To Bring New Challenges For Global Consensus On Pediatric Extrapolation
The pharmaceutical industry is cautiously optimistic about the ambitious three-year timeline decided by the International Council for Harmonisation for its new guideline on pediatric extrapolation. However, ensuring consensus on this fast-developing concept will be a challenge as more regulators will have a seat at the discussion table as ICH expands.
You may also be interested in...
US FDA's draft guidance closes loophole where sponsors could obtain an orphan designation for a pediatric subset and then be exempt from requirements to conduct pediatric studies.
European research-based pharmaceutical industry association, EFPIA, says it "makes sense" for the World Health Organization to review the concept of "stringent regulatory authorities," which is linked to a country's membership of the International Council for Harmonisation.
A new document that complements the International Council for Harmonisation's existing guideline on pediatric clinical trials is expected to reduce the likelihood of significant differences among countries on the acceptance of data generated in pediatric global drug development programs